CN Patent

CN112153969A — 用于cgrp相关障碍的瑞美吉泮

Assigned to Pfizer Ireland Pharmaceuticals · Expires 2020-12-29 · 5y expired

What this patent protects

本文公开了通过向有需要的患者给予瑞美吉泮或其药学上可接受的盐来治疗CGRP相关障碍例如偏头痛的方法。还公开了包含瑞美吉泮的药物组合物以及包含所述药物组合物和说明书的试剂盒。

USPTO Abstract

本文公开了通过向有需要的患者给予瑞美吉泮或其药学上可接受的盐来治疗CGRP相关障碍例如偏头痛的方法。还公开了包含瑞美吉泮的药物组合物以及包含所述药物组合物和说明书的试剂盒。

Drugs covered by this patent

Patent Metadata

Patent number
CN112153969A
Jurisdiction
CN
Classification
—
Expires
2020-12-29
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Ireland Pharmaceuticals
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.